Real-world outcomes for newly diagnosed multiple myeloma
Part of Cancer clinical trials.
This study collects real-world information from people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant and are starting treatment with DRd (a three-drug combination). It aims to see how well this treatment works in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with multiple myeloma for the first time (not a recurrence).
- Your doctor has said you are not eligible for a stem cell transplant.
- You started your first treatment with the combination DRd (daratumumab, lenalidomide, and dexamethasone) after September 2023.
- You are not participating in another clinical trial for your first treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well first-line immunotherapy works for people newly diagnosed with multiple myeloma in real-world clinical settings in China. The goal is to understand what treatments are used and how patients respond.
This study compares a new investigational drug (AZD0120) with a standard stem cell transplant for people with newly diagnosed multiple myeloma who have already completed initial treatment. The goal is to see if the new drug works as well as or better than the transplant in keeping the cancer from coming back.
This trial tests if adding the immunotherapy drug elranatamab (with or without lenalidomide) after initial treatment works better than the usual care for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant.
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.